Podcast appearances and mentions of nicole lamanna

In today's episode, we had the pleasure of speaking with Nicole Lamanna, MD, about patient selection considerations for the use of pirtobrutinib (Jaypirca) in the management of chronic lymphocytic leukemia (CLL). Dr Lamanna is a hematologic oncologist at the Herbert Irving Comprehensive Cancer Center at NewYork-Presbyterian/Columbia University Irving Medical Center in New York, New York. In our exclusive interview, Dr Lamanna discussed how disease progression, treatment intolerance, and prior therapy exposure inform the decision to initiate pirtobrutinib in patients with CLL. She also highlighted important clinical features that guide the use of noncovalent BTK inhibitors—including sequencing strategies following covalent BTK and BCL-2 inhibitors, and emphasized the importance of balancing treatment efficacy with tolerability to optimize long-term disease management in CLL.

Featuring perspectives from Dr Nicole Lamanna and Dr Kerry Rogers, including the following topics: Introduction (0:00) Current Role of Covalent Bruton Tyrosine Kinase and Bcl-2 Inhibitors in Managing Chronic Lymphocytic Leukemia — Dr Lamanna (10:55) Novel Agents and Combination Strategies — Dr Rogers (31:21) CME information and select publications

In today's episode, supported by BeiGene, Alexey Danilov, MD, PhD, hosted a discussion with Nicole Lamanna, MD, about the use of zanubrutinib (Brukinsa) in patients with chronic lymphocytic leukemia (CLL). Dr Danilov is the Marianne and Gerhard Pinkus Professor of Early Clinical Therapeutics, the medical director of the Early Phase Therapeutics Program for the Systems Clinical Trials Office, co-director of the Toni Stephenson Lymphoma Center, and a professor in the Division of Lymphoma at the Department of Hematology & Hematopoietic Cell Transplantation at City of Hope in Duarte, California. Dr Lamanna is an associate clinical professor of medicine in the Hematologic Malignancies Section of the Hematology/Oncology Division at the Columbia University Herberg Irving Comprehensive Cancer Center in New York, New York.  In our exclusive interview, Drs Danilov and Lamanna discussed key efficacy data from the final comparative analysis of the phase 3 ALPINE trial (NCT03734016) in patients with relapsed/refractory CLL, zanubrutinib-associated toxicities to consider when using this agent, and what the future looks like for BTK inhibitor–based therapy in CLL.

Featuring perspectives from Dr Nicole Lamanna, including the following topics: Introduction (0:00) Case: A man in his late 60s with IGHV-mutated chronic lymphocytic leukemia (CLL) (trisomy 12) and progressive adenopathy — Bhavana (Tina) Bhatnagar, DO (1:22) Case: A woman in her mid 70s with IGHV-unmutated, del(13q) CLL and fatigue — Erik Rupard, MD (19:57) Case: A woman in her mid 80s with del(13q) CLL under watchful waiting develops progressive symptoms — Shams Bufalino, MD (30:00) Case: A woman in her early 60s diagnosed with small lymphocytic leukemia (SLL) now with disease progression on ibrutinib — Warren S Brenner, MD (33:08) Current role of pirtobrutinib; CAR T-cell therapy; Richter's transformation — Dr Brenner (36:04) Case: A man in his mid 40s with SLL who received second-line venetoclax/rituximab — Yanjun Ma, MD (50:01) CME information and select publications

Dr Nicole Lamanna from the Columbia University Herbert Irving Comprehensive Cancer Center in New York, New York, discusses recent updates on available and novel treatment strategies for chronic lymphocytic leukemia.

Dr Nicole Lamanna from the Columbia University Herbert Irving Comprehensive Cancer Center in New York, New York, discusses recent updates on available and novel treatment strategies for chronic lymphocytic leukemia, moderated by Dr Neil Love. Produced by Research To Practice. CME information and select publications here (https://www.researchtopractice.com/MTPCLL24/Part2).

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/UNN865. CME credit will be available until June 11, 2025.Redefining Frontlines in CLL: Key Questions on the Role of CIT, BTKi Standards, and Innovative BTKi Combinations In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent educational grant from AstraZeneca.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/UNN865. CME credit will be available until June 11, 2025.Redefining Frontlines in CLL: Key Questions on the Role of CIT, BTKi Standards, and Innovative BTKi Combinations In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent educational grant from AstraZeneca.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/UNN865. CME credit will be available until June 11, 2025.Redefining Frontlines in CLL: Key Questions on the Role of CIT, BTKi Standards, and Innovative BTKi Combinations In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent educational grant from AstraZeneca.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/UNN865. CME credit will be available until June 11, 2025.Redefining Frontlines in CLL: Key Questions on the Role of CIT, BTKi Standards, and Innovative BTKi Combinations In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent educational grant from AstraZeneca.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/UNN865. CME credit will be available until June 11, 2025.Redefining Frontlines in CLL: Key Questions on the Role of CIT, BTKi Standards, and Innovative BTKi Combinations In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent educational grant from AstraZeneca.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/UNN865. CME credit will be available until June 11, 2025.Redefining Frontlines in CLL: Key Questions on the Role of CIT, BTKi Standards, and Innovative BTKi Combinations In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent educational grant from AstraZeneca.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC information, and to apply for credit, please visit us at PeerView.com/YUZ865. CME/MOC credit will be available until December 31, 2024.Controlling and Conquering CLL: Guidance on Modern Targeted Options, Innovative Combinations, and Sequential ManagementPenn State College of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.This activity is developed in collaboration with our educational partners, PVI, PeerView Institute for Medical Education, and CLL Society.SupportThis activity is supported by independent educational grants from AbbVie; AstraZeneca; Lilly; and Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.DisclosuresProf. John G. Gribben, MD, DSc, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Amgen and Gilead Sciences/Kite.Grant/Research Support from AstraZeneca.John N. Allan, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie; Adaptive Biotechnologies; ADC Therapeutics; AstraZeneca; BeiGene, Inc.; Epizyme, Inc.; Genentech, Inc.; Janssen Pharmaceuticals, Inc.; LAVA Therapeutics; Lilly; Pharmacyclics LLC; and TG Therapeutics, Inc.Grant/Research Support from BeiGene, Inc.; Genentech, Inc.; and Janssen Pharmaceuticals, Inc.Speaker for AbbVie; BeiGene, Inc.; Janssen Pharmaceuticals, Inc.; and Pharmacyclics LLC.Nicole Lamanna, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie; Adaptive Biotechnologies; Allogene Therapeutics; AstraZeneca; BeiGene, Inc.; Genentech, Inc.; Janssen Pharmaceuticals, Inc.; Lilly/Loxo Oncology, Inc.; and Pharmacyclics LLC.Grant/Research Support from AbbVie; AstraZeneca; BeiGene, Inc.; Genentech, Inc.; Lilly/Loxo Oncology, Inc.; MingSight Pharmaceuticals, Inc.; Octapharma USA, Inc.; Oncternal Therapeutics; and TG Therapeutics, Inc.Meghan C. Thompson, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AstraZeneca; Lilly/Loxo Oncology, Inc.; and Pharmacyclics LLC/Janssen Pharmaceuticals, Inc.Grant/Research Support from AbbVie; AstraZeneca; BeiGene, Inc.; Genentech, Inc.; Genmab; and Nurix Therapeutics. Research funding goes to Institution.Honoraria from Brazilian Association of Hematology; Curio Science; Dava Oncology; Hemotherapy and Cellular Therapy (ABHH); Intellisphere LLC; Massachusetts Medical Society; MJH Life Sciences; Phillips Group Oncology Communications; and VJHemOnc.Larry Marion has no financial interests/relationships or affiliations in relation to this activity.Other PVI staff who may potentially review content for this activity have disclosed no relevant financial relationships.Penn State College of Medicine staff and faculty involved in the development and review of this activity have disclosed no relevant financial relationships.All of the relevant financial relationships listed for these individuals have been mitigated.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC information, and to apply for credit, please visit us at PeerView.com/YUZ865. CME/MOC credit will be available until December 31, 2024.Controlling and Conquering CLL: Guidance on Modern Targeted Options, Innovative Combinations, and Sequential ManagementPenn State College of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.This activity is developed in collaboration with our educational partners, PVI, PeerView Institute for Medical Education, and CLL Society.SupportThis activity is supported by independent educational grants from AbbVie; AstraZeneca; Lilly; and Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.DisclosuresProf. John G. Gribben, MD, DSc, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Amgen and Gilead Sciences/Kite.Grant/Research Support from AstraZeneca.John N. Allan, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie; Adaptive Biotechnologies; ADC Therapeutics; AstraZeneca; BeiGene, Inc.; Epizyme, Inc.; Genentech, Inc.; Janssen Pharmaceuticals, Inc.; LAVA Therapeutics; Lilly; Pharmacyclics LLC; and TG Therapeutics, Inc.Grant/Research Support from BeiGene, Inc.; Genentech, Inc.; and Janssen Pharmaceuticals, Inc.Speaker for AbbVie; BeiGene, Inc.; Janssen Pharmaceuticals, Inc.; and Pharmacyclics LLC.Nicole Lamanna, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie; Adaptive Biotechnologies; Allogene Therapeutics; AstraZeneca; BeiGene, Inc.; Genentech, Inc.; Janssen Pharmaceuticals, Inc.; Lilly/Loxo Oncology, Inc.; and Pharmacyclics LLC.Grant/Research Support from AbbVie; AstraZeneca; BeiGene, Inc.; Genentech, Inc.; Lilly/Loxo Oncology, Inc.; MingSight Pharmaceuticals, Inc.; Octapharma USA, Inc.; Oncternal Therapeutics; and TG Therapeutics, Inc.Meghan C. Thompson, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AstraZeneca; Lilly/Loxo Oncology, Inc.; and Pharmacyclics LLC/Janssen Pharmaceuticals, Inc.Grant/Research Support from AbbVie; AstraZeneca; BeiGene, Inc.; Genentech, Inc.; Genmab; and Nurix Therapeutics. Research funding goes to Institution.Honoraria from Brazilian Association of Hematology; Curio Science; Dava Oncology; Hemotherapy and Cellular Therapy (ABHH); Intellisphere LLC; Massachusetts Medical Society; MJH Life Sciences; Phillips Group Oncology Communications; and VJHemOnc.Larry Marion has no financial interests/relationships or affiliations in relation to this activity.Other PVI staff who may potentially review content for this activity have disclosed no relevant financial relationships.Penn State College of Medicine staff and faculty involved in the development and review of this activity have disclosed no relevant financial relationships.All of the relevant financial relationships listed for these individuals have been mitigated.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC information, and to apply for credit, please visit us at PeerView.com/YUZ865. CME/MOC credit will be available until December 31, 2024.Controlling and Conquering CLL: Guidance on Modern Targeted Options, Innovative Combinations, and Sequential ManagementPenn State College of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.This activity is developed in collaboration with our educational partners, PVI, PeerView Institute for Medical Education, and CLL Society.SupportThis activity is supported by independent educational grants from AbbVie; AstraZeneca; Lilly; and Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.DisclosuresProf. John G. Gribben, MD, DSc, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Amgen and Gilead Sciences/Kite.Grant/Research Support from AstraZeneca.John N. Allan, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie; Adaptive Biotechnologies; ADC Therapeutics; AstraZeneca; BeiGene, Inc.; Epizyme, Inc.; Genentech, Inc.; Janssen Pharmaceuticals, Inc.; LAVA Therapeutics; Lilly; Pharmacyclics LLC; and TG Therapeutics, Inc.Grant/Research Support from BeiGene, Inc.; Genentech, Inc.; and Janssen Pharmaceuticals, Inc.Speaker for AbbVie; BeiGene, Inc.; Janssen Pharmaceuticals, Inc.; and Pharmacyclics LLC.Nicole Lamanna, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie; Adaptive Biotechnologies; Allogene Therapeutics; AstraZeneca; BeiGene, Inc.; Genentech, Inc.; Janssen Pharmaceuticals, Inc.; Lilly/Loxo Oncology, Inc.; and Pharmacyclics LLC.Grant/Research Support from AbbVie; AstraZeneca; BeiGene, Inc.; Genentech, Inc.; Lilly/Loxo Oncology, Inc.; MingSight Pharmaceuticals, Inc.; Octapharma USA, Inc.; Oncternal Therapeutics; and TG Therapeutics, Inc.Meghan C. Thompson, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AstraZeneca; Lilly/Loxo Oncology, Inc.; and Pharmacyclics LLC/Janssen Pharmaceuticals, Inc.Grant/Research Support from AbbVie; AstraZeneca; BeiGene, Inc.; Genentech, Inc.; Genmab; and Nurix Therapeutics. Research funding goes to Institution.Honoraria from Brazilian Association of Hematology; Curio Science; Dava Oncology; Hemotherapy and Cellular Therapy (ABHH); Intellisphere LLC; Massachusetts Medical Society; MJH Life Sciences; Phillips Group Oncology Communications; and VJHemOnc.Larry Marion has no financial interests/relationships or affiliations in relation to this activity.Other PVI staff who may potentially review content for this activity have disclosed no relevant financial relationships.Penn State College of Medicine staff and faculty involved in the development and review of this activity have disclosed no relevant financial relationships.All of the relevant financial relationships listed for these individuals have been mitigated.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC information, and to apply for credit, please visit us at PeerView.com/YUZ865. CME/MOC credit will be available until December 31, 2024.Controlling and Conquering CLL: Guidance on Modern Targeted Options, Innovative Combinations, and Sequential ManagementPenn State College of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.This activity is developed in collaboration with our educational partners, PVI, PeerView Institute for Medical Education, and CLL Society.SupportThis activity is supported by independent educational grants from AbbVie; AstraZeneca; Lilly; and Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.DisclosuresProf. John G. Gribben, MD, DSc, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Amgen and Gilead Sciences/Kite.Grant/Research Support from AstraZeneca.John N. Allan, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie; Adaptive Biotechnologies; ADC Therapeutics; AstraZeneca; BeiGene, Inc.; Epizyme, Inc.; Genentech, Inc.; Janssen Pharmaceuticals, Inc.; LAVA Therapeutics; Lilly; Pharmacyclics LLC; and TG Therapeutics, Inc.Grant/Research Support from BeiGene, Inc.; Genentech, Inc.; and Janssen Pharmaceuticals, Inc.Speaker for AbbVie; BeiGene, Inc.; Janssen Pharmaceuticals, Inc.; and Pharmacyclics LLC.Nicole Lamanna, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie; Adaptive Biotechnologies; Allogene Therapeutics; AstraZeneca; BeiGene, Inc.; Genentech, Inc.; Janssen Pharmaceuticals, Inc.; Lilly/Loxo Oncology, Inc.; and Pharmacyclics LLC.Grant/Research Support from AbbVie; AstraZeneca; BeiGene, Inc.; Genentech, Inc.; Lilly/Loxo Oncology, Inc.; MingSight Pharmaceuticals, Inc.; Octapharma USA, Inc.; Oncternal Therapeutics; and TG Therapeutics, Inc.Meghan C. Thompson, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AstraZeneca; Lilly/Loxo Oncology, Inc.; and Pharmacyclics LLC/Janssen Pharmaceuticals, Inc.Grant/Research Support from AbbVie; AstraZeneca; BeiGene, Inc.; Genentech, Inc.; Genmab; and Nurix Therapeutics. Research funding goes to Institution.Honoraria from Brazilian Association of Hematology; Curio Science; Dava Oncology; Hemotherapy and Cellular Therapy (ABHH); Intellisphere LLC; Massachusetts Medical Society; MJH Life Sciences; Phillips Group Oncology Communications; and VJHemOnc.Larry Marion has no financial interests/relationships or affiliations in relation to this activity.Other PVI staff who may potentially review content for this activity have disclosed no relevant financial relationships.Penn State College of Medicine staff and faculty involved in the development and review of this activity have disclosed no relevant financial relationships.All of the relevant financial relationships listed for these individuals have been mitigated.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC information, and to apply for credit, please visit us at PeerView.com/YUZ865. CME/MOC credit will be available until December 31, 2024.Controlling and Conquering CLL: Guidance on Modern Targeted Options, Innovative Combinations, and Sequential ManagementPenn State College of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.This activity is developed in collaboration with our educational partners, PVI, PeerView Institute for Medical Education, and CLL Society.SupportThis activity is supported by independent educational grants from AbbVie; AstraZeneca; Lilly; and Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.DisclosuresProf. John G. Gribben, MD, DSc, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Amgen and Gilead Sciences/Kite.Grant/Research Support from AstraZeneca.John N. Allan, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie; Adaptive Biotechnologies; ADC Therapeutics; AstraZeneca; BeiGene, Inc.; Epizyme, Inc.; Genentech, Inc.; Janssen Pharmaceuticals, Inc.; LAVA Therapeutics; Lilly; Pharmacyclics LLC; and TG Therapeutics, Inc.Grant/Research Support from BeiGene, Inc.; Genentech, Inc.; and Janssen Pharmaceuticals, Inc.Speaker for AbbVie; BeiGene, Inc.; Janssen Pharmaceuticals, Inc.; and Pharmacyclics LLC.Nicole Lamanna, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie; Adaptive Biotechnologies; Allogene Therapeutics; AstraZeneca; BeiGene, Inc.; Genentech, Inc.; Janssen Pharmaceuticals, Inc.; Lilly/Loxo Oncology, Inc.; and Pharmacyclics LLC.Grant/Research Support from AbbVie; AstraZeneca; BeiGene, Inc.; Genentech, Inc.; Lilly/Loxo Oncology, Inc.; MingSight Pharmaceuticals, Inc.; Octapharma USA, Inc.; Oncternal Therapeutics; and TG Therapeutics, Inc.Meghan C. Thompson, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AstraZeneca; Lilly/Loxo Oncology, Inc.; and Pharmacyclics LLC/Janssen Pharmaceuticals, Inc.Grant/Research Support from AbbVie; AstraZeneca; BeiGene, Inc.; Genentech, Inc.; Genmab; and Nurix Therapeutics. Research funding goes to Institution.Honoraria from Brazilian Association of Hematology; Curio Science; Dava Oncology; Hemotherapy and Cellular Therapy (ABHH); Intellisphere LLC; Massachusetts Medical Society; MJH Life Sciences; Phillips Group Oncology Communications; and VJHemOnc.Larry Marion has no financial interests/relationships or affiliations in relation to this activity.Other PVI staff who may potentially review content for this activity have disclosed no relevant financial relationships.Penn State College of Medicine staff and faculty involved in the development and review of this activity have disclosed no relevant financial relationships.All of the relevant financial relationships listed for these individuals have been mitigated.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC information, and to apply for credit, please visit us at PeerView.com/YUZ865. CME/MOC credit will be available until December 31, 2024.Controlling and Conquering CLL: Guidance on Modern Targeted Options, Innovative Combinations, and Sequential ManagementPenn State College of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.This activity is developed in collaboration with our educational partners, PVI, PeerView Institute for Medical Education, and CLL Society.SupportThis activity is supported by independent educational grants from AbbVie; AstraZeneca; Lilly; and Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.DisclosuresProf. John G. Gribben, MD, DSc, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Amgen and Gilead Sciences/Kite.Grant/Research Support from AstraZeneca.John N. Allan, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie; Adaptive Biotechnologies; ADC Therapeutics; AstraZeneca; BeiGene, Inc.; Epizyme, Inc.; Genentech, Inc.; Janssen Pharmaceuticals, Inc.; LAVA Therapeutics; Lilly; Pharmacyclics LLC; and TG Therapeutics, Inc.Grant/Research Support from BeiGene, Inc.; Genentech, Inc.; and Janssen Pharmaceuticals, Inc.Speaker for AbbVie; BeiGene, Inc.; Janssen Pharmaceuticals, Inc.; and Pharmacyclics LLC.Nicole Lamanna, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie; Adaptive Biotechnologies; Allogene Therapeutics; AstraZeneca; BeiGene, Inc.; Genentech, Inc.; Janssen Pharmaceuticals, Inc.; Lilly/Loxo Oncology, Inc.; and Pharmacyclics LLC.Grant/Research Support from AbbVie; AstraZeneca; BeiGene, Inc.; Genentech, Inc.; Lilly/Loxo Oncology, Inc.; MingSight Pharmaceuticals, Inc.; Octapharma USA, Inc.; Oncternal Therapeutics; and TG Therapeutics, Inc.Meghan C. Thompson, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AstraZeneca; Lilly/Loxo Oncology, Inc.; and Pharmacyclics LLC/Janssen Pharmaceuticals, Inc.Grant/Research Support from AbbVie; AstraZeneca; BeiGene, Inc.; Genentech, Inc.; Genmab; and Nurix Therapeutics. Research funding goes to Institution.Honoraria from Brazilian Association of Hematology; Curio Science; Dava Oncology; Hemotherapy and Cellular Therapy (ABHH); Intellisphere LLC; Massachusetts Medical Society; MJH Life Sciences; Phillips Group Oncology Communications; and VJHemOnc.Larry Marion has no financial interests/relationships or affiliations in relation to this activity.Other PVI staff who may potentially review content for this activity have disclosed no relevant financial relationships.Penn State College of Medicine staff and faculty involved in the development and review of this activity have disclosed no relevant financial relationships.All of the relevant financial relationships listed for these individuals have been mitigated.

Go online to PeerView.com/KBW860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Innovative therapeutics have transformed the management of chronic lymphocytic leukemia (CLL) and allowed patients a greater range of treatment options. Covalent BTK inhibitors (BTKi) and BCL2 inhibitors (BCL2i) have demonstrated efficacy in a wide variety of treatment settings, and newer, non-covalent BTKi are poised to overcome long-standing therapeutic standards. Do you have the tools needed to “level up” your practice? Find out in this “Clinical Consults” activity based on a symposium that was recorded at the Society of Hematologic Oncology's 11th Annual Meeting. Throughout this program, a panel of leading CLL experts use conversational, case-based dialogue to provide guidance on integrating modern therapeutics anchored by BTKi and BCL2i regimens, along with rapidly emerging non-covalent BTKi and BTKi-BCL2i combinations. Join the leading lights of CLL, sharpen your therapeutic skills, and reach the next level of CLL care today! Upon completion of this activity, participants should be better able to: Cite current evidence and updated practice guidelines supporting the use of targeted agents and emerging treatment options in CLL, such as BTK and BCL2 inhibitors, CAR-T, and bispecifics; Develop personalized management protocols that include established and emerging targeted strategies as single-agent and combination platforms for patients with treatment-naïve CLL based on prognostic information, the presence of comorbidities, and safety considerations; Implement sequential treatment plans with targeted options for patients with therapeutic intolerance and/or relapsed/refractory CLL; and Manage safety and care delivery considerations associated with the use of targeted agents and other newer therapeutics in the CLL setting

Go online to PeerView.com/KBW860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Innovative therapeutics have transformed the management of chronic lymphocytic leukemia (CLL) and allowed patients a greater range of treatment options. Covalent BTK inhibitors (BTKi) and BCL2 inhibitors (BCL2i) have demonstrated efficacy in a wide variety of treatment settings, and newer, non-covalent BTKi are poised to overcome long-standing therapeutic standards. Do you have the tools needed to “level up” your practice? Find out in this “Clinical Consults” activity based on a symposium that was recorded at the Society of Hematologic Oncology's 11th Annual Meeting. Throughout this program, a panel of leading CLL experts use conversational, case-based dialogue to provide guidance on integrating modern therapeutics anchored by BTKi and BCL2i regimens, along with rapidly emerging non-covalent BTKi and BTKi-BCL2i combinations. Join the leading lights of CLL, sharpen your therapeutic skills, and reach the next level of CLL care today! Upon completion of this activity, participants should be better able to: Cite current evidence and updated practice guidelines supporting the use of targeted agents and emerging treatment options in CLL, such as BTK and BCL2 inhibitors, CAR-T, and bispecifics; Develop personalized management protocols that include established and emerging targeted strategies as single-agent and combination platforms for patients with treatment-naïve CLL based on prognostic information, the presence of comorbidities, and safety considerations; Implement sequential treatment plans with targeted options for patients with therapeutic intolerance and/or relapsed/refractory CLL; and Manage safety and care delivery considerations associated with the use of targeted agents and other newer therapeutics in the CLL setting

Go online to PeerView.com/KBW860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Innovative therapeutics have transformed the management of chronic lymphocytic leukemia (CLL) and allowed patients a greater range of treatment options. Covalent BTK inhibitors (BTKi) and BCL2 inhibitors (BCL2i) have demonstrated efficacy in a wide variety of treatment settings, and newer, non-covalent BTKi are poised to overcome long-standing therapeutic standards. Do you have the tools needed to “level up” your practice? Find out in this “Clinical Consults” activity based on a symposium that was recorded at the Society of Hematologic Oncology's 11th Annual Meeting. Throughout this program, a panel of leading CLL experts use conversational, case-based dialogue to provide guidance on integrating modern therapeutics anchored by BTKi and BCL2i regimens, along with rapidly emerging non-covalent BTKi and BTKi-BCL2i combinations. Join the leading lights of CLL, sharpen your therapeutic skills, and reach the next level of CLL care today! Upon completion of this activity, participants should be better able to: Cite current evidence and updated practice guidelines supporting the use of targeted agents and emerging treatment options in CLL, such as BTK and BCL2 inhibitors, CAR-T, and bispecifics; Develop personalized management protocols that include established and emerging targeted strategies as single-agent and combination platforms for patients with treatment-naïve CLL based on prognostic information, the presence of comorbidities, and safety considerations; Implement sequential treatment plans with targeted options for patients with therapeutic intolerance and/or relapsed/refractory CLL; and Manage safety and care delivery considerations associated with the use of targeted agents and other newer therapeutics in the CLL setting

Go online to PeerView.com/KBW860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Innovative therapeutics have transformed the management of chronic lymphocytic leukemia (CLL) and allowed patients a greater range of treatment options. Covalent BTK inhibitors (BTKi) and BCL2 inhibitors (BCL2i) have demonstrated efficacy in a wide variety of treatment settings, and newer, non-covalent BTKi are poised to overcome long-standing therapeutic standards. Do you have the tools needed to “level up” your practice? Find out in this “Clinical Consults” activity based on a symposium that was recorded at the Society of Hematologic Oncology's 11th Annual Meeting. Throughout this program, a panel of leading CLL experts use conversational, case-based dialogue to provide guidance on integrating modern therapeutics anchored by BTKi and BCL2i regimens, along with rapidly emerging non-covalent BTKi and BTKi-BCL2i combinations. Join the leading lights of CLL, sharpen your therapeutic skills, and reach the next level of CLL care today! Upon completion of this activity, participants should be better able to: Cite current evidence and updated practice guidelines supporting the use of targeted agents and emerging treatment options in CLL, such as BTK and BCL2 inhibitors, CAR-T, and bispecifics; Develop personalized management protocols that include established and emerging targeted strategies as single-agent and combination platforms for patients with treatment-naïve CLL based on prognostic information, the presence of comorbidities, and safety considerations; Implement sequential treatment plans with targeted options for patients with therapeutic intolerance and/or relapsed/refractory CLL; and Manage safety and care delivery considerations associated with the use of targeted agents and other newer therapeutics in the CLL setting

Go online to PeerView.com/KBW860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Innovative therapeutics have transformed the management of chronic lymphocytic leukemia (CLL) and allowed patients a greater range of treatment options. Covalent BTK inhibitors (BTKi) and BCL2 inhibitors (BCL2i) have demonstrated efficacy in a wide variety of treatment settings, and newer, non-covalent BTKi are poised to overcome long-standing therapeutic standards. Do you have the tools needed to “level up” your practice? Find out in this “Clinical Consults” activity based on a symposium that was recorded at the Society of Hematologic Oncology's 11th Annual Meeting. Throughout this program, a panel of leading CLL experts use conversational, case-based dialogue to provide guidance on integrating modern therapeutics anchored by BTKi and BCL2i regimens, along with rapidly emerging non-covalent BTKi and BTKi-BCL2i combinations. Join the leading lights of CLL, sharpen your therapeutic skills, and reach the next level of CLL care today! Upon completion of this activity, participants should be better able to: Cite current evidence and updated practice guidelines supporting the use of targeted agents and emerging treatment options in CLL, such as BTK and BCL2 inhibitors, CAR-T, and bispecifics; Develop personalized management protocols that include established and emerging targeted strategies as single-agent and combination platforms for patients with treatment-naïve CLL based on prognostic information, the presence of comorbidities, and safety considerations; Implement sequential treatment plans with targeted options for patients with therapeutic intolerance and/or relapsed/refractory CLL; and Manage safety and care delivery considerations associated with the use of targeted agents and other newer therapeutics in the CLL setting

Go online to PeerView.com/KBW860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Innovative therapeutics have transformed the management of chronic lymphocytic leukemia (CLL) and allowed patients a greater range of treatment options. Covalent BTK inhibitors (BTKi) and BCL2 inhibitors (BCL2i) have demonstrated efficacy in a wide variety of treatment settings, and newer, non-covalent BTKi are poised to overcome long-standing therapeutic standards. Do you have the tools needed to “level up” your practice? Find out in this “Clinical Consults” activity based on a symposium that was recorded at the Society of Hematologic Oncology's 11th Annual Meeting. Throughout this program, a panel of leading CLL experts use conversational, case-based dialogue to provide guidance on integrating modern therapeutics anchored by BTKi and BCL2i regimens, along with rapidly emerging non-covalent BTKi and BTKi-BCL2i combinations. Join the leading lights of CLL, sharpen your therapeutic skills, and reach the next level of CLL care today! Upon completion of this activity, participants should be better able to: Cite current evidence and updated practice guidelines supporting the use of targeted agents and emerging treatment options in CLL, such as BTK and BCL2 inhibitors, CAR-T, and bispecifics; Develop personalized management protocols that include established and emerging targeted strategies as single-agent and combination platforms for patients with treatment-naïve CLL based on prognostic information, the presence of comorbidities, and safety considerations; Implement sequential treatment plans with targeted options for patients with therapeutic intolerance and/or relapsed/refractory CLL; and Manage safety and care delivery considerations associated with the use of targeted agents and other newer therapeutics in the CLL setting

Featuring perspectives from Dr Nicole Lamanna and Dr William G Wierda, including the following topics: Introduction: Mentoring Fellows (0:00) Case: A woman in her mid 50s with multiple cardiovascular comorbidities and relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) receives bendamustine/rituximab induction followed by venetoclax/rituximab consolidation in a clinical trial — Spencer Henick Bachow, MD (11:47) Case: A man in his late 70s with relapsed del(11q) CLL develops atrial fibrillation while receiving ibrutinib — Warren S Brenner, MD (18:15) Case: A man in his early 70s with CLL develops rash and bruising while receiving ibrutinib — Gigi Chen, MD (27:02) Case: A man in his late 80s with CLL receives acalabrutinib as initial therapy and experiences thrombocytopenia — Kapisthalam (KS) Kumar, MD (31:42) Case: A woman in her mid 80s with relapsed CLL (TP53 mutation) discontinues ibrutinib due to bruising — Dr Brenner (40:08) Case: A man in his early 80s with R/R mantle cell lymphoma discontinues ibrutinib due to bleeding risks after a traumatic head injury — Dr Bachow (49:01) Case: A man in his late 50s with CLL and response to acalabrutinib develops worsening myalgias a year later — Eric H Lee, MD, PhD (58:36) CME information and select publications

Dr Nicole Lamanna from the Columbia University Herbert Irving Comprehensive Cancer Center in New York, New York, and Dr William G Wierda from The University of Texas MD Anderson Cancer Center in Houston, Texas, discuss the spectrum of toxicities associated with BTK inhibitors and strategies for their mitigation and management for patients with chronic lymphocytic leukemia and mantle cell lymphoma, moderated by Dr Neil Love. Produced by Research To Practice. CME information and select publications here (https://www.researchtopractice.com/BTKToxicities23)

Dr Nicole Lamanna from the Columbia University Herbert Irving Comprehensive Cancer Center in New York, New York, and Dr William G Wierda from The University of Texas MD Anderson Cancer Center in Houston, Texas, discuss the spectrum of toxicities associated with BTK inhibitors and strategies for their mitigation and management for patients with chronic lymphocytic leukemia and mantle cell lymphoma.

As treatment options increase for patients with CLL, so do questions about which interventions, if any, are right for which patients and when. Bob Figlin, MD, and Nicole Lamanna, MD, discuss key considerations, ranging from cardiac toxicity to why Dr. Lamanna “won't just treat for a symptom.”

Go online to PeerView.com/TBV860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. BTK inhibitors have transformed the medical management of chronic lymphocytic leukemia (CLL) and led to similar advances for patients with mantle cell lymphoma (MCL) and other B-cell malignancies. These therapeutics have dramatically improved outcomes for patients but have also introduced challenges regarding optimal AE management because BTK inhibitors have unique safety profiles that differ from increasingly outdated immunochemotherapy regimens. In this activity, a panel of hematology-oncology experts utilize short lectures and case-based discussions to illustrate how the interprofessional, multidisciplinary team can use safety considerations to select therapy, manage unique and challenging AEs, educate and counsel patients, and ensure vastly improved outcomes for patients with CLL, MCL, and other B-cell cancers. Upon completion of this activity, participants should be better able to: Summarize current safety considerations with first- and second-generation BTK inhibitors, including mechanistic aspects that affect toxicity, head-to-safety data, and general class-wide AE issues; Manage and mitigate toxicity associated with BTK inhibitors, including through active interventions and judicious treatment selection; and Develop team strategies for safety management that include multidisciplinary collaboration, safety-informed treatment selection, and outreach to patients with B-cell cancers receiving BTK inhibitor therapy

Go online to PeerView.com/TBV860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. BTK inhibitors have transformed the medical management of chronic lymphocytic leukemia (CLL) and led to similar advances for patients with mantle cell lymphoma (MCL) and other B-cell malignancies. These therapeutics have dramatically improved outcomes for patients but have also introduced challenges regarding optimal AE management because BTK inhibitors have unique safety profiles that differ from increasingly outdated immunochemotherapy regimens. In this activity, a panel of hematology-oncology experts utilize short lectures and case-based discussions to illustrate how the interprofessional, multidisciplinary team can use safety considerations to select therapy, manage unique and challenging AEs, educate and counsel patients, and ensure vastly improved outcomes for patients with CLL, MCL, and other B-cell cancers. Upon completion of this activity, participants should be better able to: Summarize current safety considerations with first- and second-generation BTK inhibitors, including mechanistic aspects that affect toxicity, head-to-safety data, and general class-wide AE issues; Manage and mitigate toxicity associated with BTK inhibitors, including through active interventions and judicious treatment selection; and Develop team strategies for safety management that include multidisciplinary collaboration, safety-informed treatment selection, and outreach to patients with B-cell cancers receiving BTK inhibitor therapy

Go online to PeerView.com/TBV860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. BTK inhibitors have transformed the medical management of chronic lymphocytic leukemia (CLL) and led to similar advances for patients with mantle cell lymphoma (MCL) and other B-cell malignancies. These therapeutics have dramatically improved outcomes for patients but have also introduced challenges regarding optimal AE management because BTK inhibitors have unique safety profiles that differ from increasingly outdated immunochemotherapy regimens. In this activity, a panel of hematology-oncology experts utilize short lectures and case-based discussions to illustrate how the interprofessional, multidisciplinary team can use safety considerations to select therapy, manage unique and challenging AEs, educate and counsel patients, and ensure vastly improved outcomes for patients with CLL, MCL, and other B-cell cancers. Upon completion of this activity, participants should be better able to: Summarize current safety considerations with first- and second-generation BTK inhibitors, including mechanistic aspects that affect toxicity, head-to-safety data, and general class-wide AE issues; Manage and mitigate toxicity associated with BTK inhibitors, including through active interventions and judicious treatment selection; and Develop team strategies for safety management that include multidisciplinary collaboration, safety-informed treatment selection, and outreach to patients with B-cell cancers receiving BTK inhibitor therapy

Go online to PeerView.com/TBV860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. BTK inhibitors have transformed the medical management of chronic lymphocytic leukemia (CLL) and led to similar advances for patients with mantle cell lymphoma (MCL) and other B-cell malignancies. These therapeutics have dramatically improved outcomes for patients but have also introduced challenges regarding optimal AE management because BTK inhibitors have unique safety profiles that differ from increasingly outdated immunochemotherapy regimens. In this activity, a panel of hematology-oncology experts utilize short lectures and case-based discussions to illustrate how the interprofessional, multidisciplinary team can use safety considerations to select therapy, manage unique and challenging AEs, educate and counsel patients, and ensure vastly improved outcomes for patients with CLL, MCL, and other B-cell cancers. Upon completion of this activity, participants should be better able to: Summarize current safety considerations with first- and second-generation BTK inhibitors, including mechanistic aspects that affect toxicity, head-to-safety data, and general class-wide AE issues; Manage and mitigate toxicity associated with BTK inhibitors, including through active interventions and judicious treatment selection; and Develop team strategies for safety management that include multidisciplinary collaboration, safety-informed treatment selection, and outreach to patients with B-cell cancers receiving BTK inhibitor therapy

Go online to PeerView.com/TBV860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. BTK inhibitors have transformed the medical management of chronic lymphocytic leukemia (CLL) and led to similar advances for patients with mantle cell lymphoma (MCL) and other B-cell malignancies. These therapeutics have dramatically improved outcomes for patients but have also introduced challenges regarding optimal AE management because BTK inhibitors have unique safety profiles that differ from increasingly outdated immunochemotherapy regimens. In this activity, a panel of hematology-oncology experts utilize short lectures and case-based discussions to illustrate how the interprofessional, multidisciplinary team can use safety considerations to select therapy, manage unique and challenging AEs, educate and counsel patients, and ensure vastly improved outcomes for patients with CLL, MCL, and other B-cell cancers. Upon completion of this activity, participants should be better able to: Summarize current safety considerations with first- and second-generation BTK inhibitors, including mechanistic aspects that affect toxicity, head-to-safety data, and general class-wide AE issues; Manage and mitigate toxicity associated with BTK inhibitors, including through active interventions and judicious treatment selection; and Develop team strategies for safety management that include multidisciplinary collaboration, safety-informed treatment selection, and outreach to patients with B-cell cancers receiving BTK inhibitor therapy

Go online to PeerView.com/TBV860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. BTK inhibitors have transformed the medical management of chronic lymphocytic leukemia (CLL) and led to similar advances for patients with mantle cell lymphoma (MCL) and other B-cell malignancies. These therapeutics have dramatically improved outcomes for patients but have also introduced challenges regarding optimal AE management because BTK inhibitors have unique safety profiles that differ from increasingly outdated immunochemotherapy regimens. In this activity, a panel of hematology-oncology experts utilize short lectures and case-based discussions to illustrate how the interprofessional, multidisciplinary team can use safety considerations to select therapy, manage unique and challenging AEs, educate and counsel patients, and ensure vastly improved outcomes for patients with CLL, MCL, and other B-cell cancers. Upon completion of this activity, participants should be better able to: Summarize current safety considerations with first- and second-generation BTK inhibitors, including mechanistic aspects that affect toxicity, head-to-safety data, and general class-wide AE issues; Manage and mitigate toxicity associated with BTK inhibitors, including through active interventions and judicious treatment selection; and Develop team strategies for safety management that include multidisciplinary collaboration, safety-informed treatment selection, and outreach to patients with B-cell cancers receiving BTK inhibitor therapy

In this episode, Farrukh T. Awan, MD, and Nicole Lamanna, MD, answer questions from an audience of healthcare professionals on topics related to the use of BTK inhibitors for the management of chronic lymphocytic leukemia (CLL). The topics covered include:Whether it is justifiable to use chlorambucil plus obinutuzumab as a control arm in a registrational trial todayRelevance of overall response rate vs progression-free survival for BTK inhibitor therapyApproval of ibrutinib/venetoclax combination therapy for patients with CLLKey differences between zanubrutinib and acalabrutinib in the treatment of patients with CLLHow to transition/overlap next therapy in patients with CLL with progression while receiving a BTK inhibitorFaculty:Farrukh T. Awan, MDAssociate Professor of Internal MedicineDirector of Lymphoid Malignancies ProgramHarold C. Simmons Comprehensive Cancer CenterUniversity of Texas Southwestern Medical CenterDallas, TexasNicole Lamanna, MDAssociate ProfessorLeukemia ServiceDirector of CLL ProgramHematologic Malignancies SectionDepartment of MedicineNew York-Presbyterian/Columbia University Medical CenterNew York, New YorkLink to the complete program, including downloadable slidesets and an on-demand webcast:https://bit.ly/3EjvSKm

Go online to PeerView.com/XPA860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Have you caught up with therapeutic changes in chronic lymphocytic leukemia (CLL) and the latest science supporting new standards of care centered on continuous or fixed-duration therapy with targeted agents (including BTK and BCL-2 inhibitors)? In this PeerView MasterClass & Case Forum recorded at the 2022 SOHO Annual Meeting, experts give insights on how to apply this evidence and select highly personalized targeted strategies (focused on covalent and noncovalent BTK and BCL-2 inhibitor agents), when managing diverse patient populations. Watch the experts tackle challenging cases and learn strategies for selecting upfront therapy and planning sequential care in relapsed/refractory CLL. Take the challenge, see how treatment has changed, and tune in today! Upon completion of this activity, participants should be better able to: Cite updated guidelines and evidence supporting the integration of targeted drug classes in CLL, including continuous therapy, fixed-duration options, and novel combinatorial regimens; Select personalized treatment with targeted agents, including fixed-duration or continuous therapy strategies, or appropriate combinational or sequential options for patients presenting with treatment-naïve or R/R CLL; Manage treatment-emergent adverse events associated with the use of targeted agents in the CLL setting, including single-agent and combination approaches

Go online to PeerView.com/XPA860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Have you caught up with therapeutic changes in chronic lymphocytic leukemia (CLL) and the latest science supporting new standards of care centered on continuous or fixed-duration therapy with targeted agents (including BTK and BCL-2 inhibitors)? In this PeerView MasterClass & Case Forum recorded at the 2022 SOHO Annual Meeting, experts give insights on how to apply this evidence and select highly personalized targeted strategies (focused on covalent and noncovalent BTK and BCL-2 inhibitor agents), when managing diverse patient populations. Watch the experts tackle challenging cases and learn strategies for selecting upfront therapy and planning sequential care in relapsed/refractory CLL. Take the challenge, see how treatment has changed, and tune in today! Upon completion of this activity, participants should be better able to: Cite updated guidelines and evidence supporting the integration of targeted drug classes in CLL, including continuous therapy, fixed-duration options, and novel combinatorial regimens; Select personalized treatment with targeted agents, including fixed-duration or continuous therapy strategies, or appropriate combinational or sequential options for patients presenting with treatment-naïve or R/R CLL; Manage treatment-emergent adverse events associated with the use of targeted agents in the CLL setting, including single-agent and combination approaches

Go online to PeerView.com/XPA860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Have you caught up with therapeutic changes in chronic lymphocytic leukemia (CLL) and the latest science supporting new standards of care centered on continuous or fixed-duration therapy with targeted agents (including BTK and BCL-2 inhibitors)? In this PeerView MasterClass & Case Forum recorded at the 2022 SOHO Annual Meeting, experts give insights on how to apply this evidence and select highly personalized targeted strategies (focused on covalent and noncovalent BTK and BCL-2 inhibitor agents), when managing diverse patient populations. Watch the experts tackle challenging cases and learn strategies for selecting upfront therapy and planning sequential care in relapsed/refractory CLL. Take the challenge, see how treatment has changed, and tune in today! Upon completion of this activity, participants should be better able to: Cite updated guidelines and evidence supporting the integration of targeted drug classes in CLL, including continuous therapy, fixed-duration options, and novel combinatorial regimens; Select personalized treatment with targeted agents, including fixed-duration or continuous therapy strategies, or appropriate combinational or sequential options for patients presenting with treatment-naïve or R/R CLL; Manage treatment-emergent adverse events associated with the use of targeted agents in the CLL setting, including single-agent and combination approaches

Go online to PeerView.com/XPA860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Have you caught up with therapeutic changes in chronic lymphocytic leukemia (CLL) and the latest science supporting new standards of care centered on continuous or fixed-duration therapy with targeted agents (including BTK and BCL-2 inhibitors)? In this PeerView MasterClass & Case Forum recorded at the 2022 SOHO Annual Meeting, experts give insights on how to apply this evidence and select highly personalized targeted strategies (focused on covalent and noncovalent BTK and BCL-2 inhibitor agents), when managing diverse patient populations. Watch the experts tackle challenging cases and learn strategies for selecting upfront therapy and planning sequential care in relapsed/refractory CLL. Take the challenge, see how treatment has changed, and tune in today! Upon completion of this activity, participants should be better able to: Cite updated guidelines and evidence supporting the integration of targeted drug classes in CLL, including continuous therapy, fixed-duration options, and novel combinatorial regimens; Select personalized treatment with targeted agents, including fixed-duration or continuous therapy strategies, or appropriate combinational or sequential options for patients presenting with treatment-naïve or R/R CLL; Manage treatment-emergent adverse events associated with the use of targeted agents in the CLL setting, including single-agent and combination approaches

Go online to PeerView.com/XPA860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Have you caught up with therapeutic changes in chronic lymphocytic leukemia (CLL) and the latest science supporting new standards of care centered on continuous or fixed-duration therapy with targeted agents (including BTK and BCL-2 inhibitors)? In this PeerView MasterClass & Case Forum recorded at the 2022 SOHO Annual Meeting, experts give insights on how to apply this evidence and select highly personalized targeted strategies (focused on covalent and noncovalent BTK and BCL-2 inhibitor agents), when managing diverse patient populations. Watch the experts tackle challenging cases and learn strategies for selecting upfront therapy and planning sequential care in relapsed/refractory CLL. Take the challenge, see how treatment has changed, and tune in today! Upon completion of this activity, participants should be better able to: Cite updated guidelines and evidence supporting the integration of targeted drug classes in CLL, including continuous therapy, fixed-duration options, and novel combinatorial regimens; Select personalized treatment with targeted agents, including fixed-duration or continuous therapy strategies, or appropriate combinational or sequential options for patients presenting with treatment-naïve or R/R CLL; Manage treatment-emergent adverse events associated with the use of targeted agents in the CLL setting, including single-agent and combination approaches

Go online to PeerView.com/XPA860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Have you caught up with therapeutic changes in chronic lymphocytic leukemia (CLL) and the latest science supporting new standards of care centered on continuous or fixed-duration therapy with targeted agents (including BTK and BCL-2 inhibitors)? In this PeerView MasterClass & Case Forum recorded at the 2022 SOHO Annual Meeting, experts give insights on how to apply this evidence and select highly personalized targeted strategies (focused on covalent and noncovalent BTK and BCL-2 inhibitor agents), when managing diverse patient populations. Watch the experts tackle challenging cases and learn strategies for selecting upfront therapy and planning sequential care in relapsed/refractory CLL. Take the challenge, see how treatment has changed, and tune in today! Upon completion of this activity, participants should be better able to: Cite updated guidelines and evidence supporting the integration of targeted drug classes in CLL, including continuous therapy, fixed-duration options, and novel combinatorial regimens; Select personalized treatment with targeted agents, including fixed-duration or continuous therapy strategies, or appropriate combinational or sequential options for patients presenting with treatment-naïve or R/R CLL; Manage treatment-emergent adverse events associated with the use of targeted agents in the CLL setting, including single-agent and combination approaches

Go online to PeerView.com/XPA860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Have you caught up with therapeutic changes in chronic lymphocytic leukemia (CLL) and the latest science supporting new standards of care centered on continuous or fixed-duration therapy with targeted agents (including BTK and BCL-2 inhibitors)? In this PeerView MasterClass & Case Forum recorded at the 2022 SOHO Annual Meeting, experts give insights on how to apply this evidence and select highly personalized targeted strategies (focused on covalent and noncovalent BTK and BCL-2 inhibitor agents), when managing diverse patient populations. Watch the experts tackle challenging cases and learn strategies for selecting upfront therapy and planning sequential care in relapsed/refractory CLL. Take the challenge, see how treatment has changed, and tune in today! Upon completion of this activity, participants should be better able to: Cite updated guidelines and evidence supporting the integration of targeted drug classes in CLL, including continuous therapy, fixed-duration options, and novel combinatorial regimens; Select personalized treatment with targeted agents, including fixed-duration or continuous therapy strategies, or appropriate combinational or sequential options for patients presenting with treatment-naïve or R/R CLL; Manage treatment-emergent adverse events associated with the use of targeted agents in the CLL setting, including single-agent and combination approaches

Go online to PeerView.com/XPA860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Have you caught up with therapeutic changes in chronic lymphocytic leukemia (CLL) and the latest science supporting new standards of care centered on continuous or fixed-duration therapy with targeted agents (including BTK and BCL-2 inhibitors)? In this PeerView MasterClass & Case Forum recorded at the 2022 SOHO Annual Meeting, experts give insights on how to apply this evidence and select highly personalized targeted strategies (focused on covalent and noncovalent BTK and BCL-2 inhibitor agents), when managing diverse patient populations. Watch the experts tackle challenging cases and learn strategies for selecting upfront therapy and planning sequential care in relapsed/refractory CLL. Take the challenge, see how treatment has changed, and tune in today! Upon completion of this activity, participants should be better able to: Cite updated guidelines and evidence supporting the integration of targeted drug classes in CLL, including continuous therapy, fixed-duration options, and novel combinatorial regimens; Select personalized treatment with targeted agents, including fixed-duration or continuous therapy strategies, or appropriate combinational or sequential options for patients presenting with treatment-naïve or R/R CLL; Manage treatment-emergent adverse events associated with the use of targeted agents in the CLL setting, including single-agent and combination approaches

Host: Jacob Sands, MD Guest: Nicole Lamanna, MD When determining a patient's therapy regimen, what disease-related factors do we need to keep in mind? Dr. Nicole Lamanna, a Hematologist/Oncologist at Columbia University Medical Center, share strategies for tailoring chronic lymphocytic leukemia treatment and how that can impact patient outcomes.

Go online to PeerView.com/QZB860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, two experts in chronic lymphocytic leukemia (CLL) management discuss the current evidence and clinical data supporting the use of first- and second-generation BTK inhibitors in CLL. The experts use this evidence to build a series of case scenarios designed to illustrate how professionals can seize the opportunity to personalize BTK inhibitor usage based on changing circumstances, patient features, and safety considerations. Upon completion of this accredited CE activity, participants should be better able to: Review the selectivity and safety differences between first- and second-generation BTK inhibitors with therapeutic applications in CLL, Cite updated evidence surrounding the efficacy and safety of BTK inhibitors in treatment-naïve and relapsed/refractory CLL as monotherapy or as part of novel combination regimens, Recommend single-agent, sequential, or combination strategies using BTK inhibitors in treatment-naïve or relapsed CLL, Manage the unique spectrum of adverse events associated with first- and second-generation BTK inhibitors used to treat CLL.

Go online to PeerView.com/QZB860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, two experts in chronic lymphocytic leukemia (CLL) management discuss the current evidence and clinical data supporting the use of first- and second-generation BTK inhibitors in CLL. The experts use this evidence to build a series of case scenarios designed to illustrate how professionals can seize the opportunity to personalize BTK inhibitor usage based on changing circumstances, patient features, and safety considerations. Upon completion of this accredited CE activity, participants should be better able to: Review the selectivity and safety differences between first- and second-generation BTK inhibitors with therapeutic applications in CLL, Cite updated evidence surrounding the efficacy and safety of BTK inhibitors in treatment-naïve and relapsed/refractory CLL as monotherapy or as part of novel combination regimens, Recommend single-agent, sequential, or combination strategies using BTK inhibitors in treatment-naïve or relapsed CLL, Manage the unique spectrum of adverse events associated with first- and second-generation BTK inhibitors used to treat CLL.

Go online to PeerView.com/QZB860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, two experts in chronic lymphocytic leukemia (CLL) management discuss the current evidence and clinical data supporting the use of first- and second-generation BTK inhibitors in CLL. The experts use this evidence to build a series of case scenarios designed to illustrate how professionals can seize the opportunity to personalize BTK inhibitor usage based on changing circumstances, patient features, and safety considerations. Upon completion of this accredited CE activity, participants should be better able to: Review the selectivity and safety differences between first- and second-generation BTK inhibitors with therapeutic applications in CLL, Cite updated evidence surrounding the efficacy and safety of BTK inhibitors in treatment-naïve and relapsed/refractory CLL as monotherapy or as part of novel combination regimens, Recommend single-agent, sequential, or combination strategies using BTK inhibitors in treatment-naïve or relapsed CLL, Manage the unique spectrum of adverse events associated with first- and second-generation BTK inhibitors used to treat CLL.

Go online to PeerView.com/QZB860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, two experts in chronic lymphocytic leukemia (CLL) management discuss the current evidence and clinical data supporting the use of first- and second-generation BTK inhibitors in CLL. The experts use this evidence to build a series of case scenarios designed to illustrate how professionals can seize the opportunity to personalize BTK inhibitor usage based on changing circumstances, patient features, and safety considerations. Upon completion of this accredited CE activity, participants should be better able to: Review the selectivity and safety differences between first- and second-generation BTK inhibitors with therapeutic applications in CLL, Cite updated evidence surrounding the efficacy and safety of BTK inhibitors in treatment-naïve and relapsed/refractory CLL as monotherapy or as part of novel combination regimens, Recommend single-agent, sequential, or combination strategies using BTK inhibitors in treatment-naïve or relapsed CLL, Manage the unique spectrum of adverse events associated with first- and second-generation BTK inhibitors used to treat CLL.

Go online to PeerView.com/QZB860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, two experts in chronic lymphocytic leukemia (CLL) management discuss the current evidence and clinical data supporting the use of first- and second-generation BTK inhibitors in CLL. The experts use this evidence to build a series of case scenarios designed to illustrate how professionals can seize the opportunity to personalize BTK inhibitor usage based on changing circumstances, patient features, and safety considerations. Upon completion of this accredited CE activity, participants should be better able to: Review the selectivity and safety differences between first- and second-generation BTK inhibitors with therapeutic applications in CLL, Cite updated evidence surrounding the efficacy and safety of BTK inhibitors in treatment-naïve and relapsed/refractory CLL as monotherapy or as part of novel combination regimens, Recommend single-agent, sequential, or combination strategies using BTK inhibitors in treatment-naïve or relapsed CLL, Manage the unique spectrum of adverse events associated with first- and second-generation BTK inhibitors used to treat CLL.

Go online to PeerView.com/QZB860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, two experts in chronic lymphocytic leukemia (CLL) management discuss the current evidence and clinical data supporting the use of first- and second-generation BTK inhibitors in CLL. The experts use this evidence to build a series of case scenarios designed to illustrate how professionals can seize the opportunity to personalize BTK inhibitor usage based on changing circumstances, patient features, and safety considerations. Upon completion of this accredited CE activity, participants should be better able to: Review the selectivity and safety differences between first- and second-generation BTK inhibitors with therapeutic applications in CLL, Cite updated evidence surrounding the efficacy and safety of BTK inhibitors in treatment-naïve and relapsed/refractory CLL as monotherapy or as part of novel combination regimens, Recommend single-agent, sequential, or combination strategies using BTK inhibitors in treatment-naïve or relapsed CLL, Manage the unique spectrum of adverse events associated with first- and second-generation BTK inhibitors used to treat CLL.

Go online to PeerView.com/UVJ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In PeerView's latest “How I Think, How I Treat” webcast, leading experts, John C. Byrd, MD, Alexey V. Danilov, MD, PhD, and Nicole Lamanna, MD, explore the current evidence that underlies the use of first- and second-generation BTK inhibitors in diseases such as CLL, MCL, and others. They also share their personal insights and intra-institutional experiences in order to illustrate what the availability of BTK inhibitor therapy has meant for their practices. Learn how the experts have adapted to the BTK era! Upon completion of this activity, participants should be better able to: Describe the anticancer mechanisms of first- and second-generation BTK inhibitors, Cite updated guidelines and evidence surrounding the efficacy and safety of first- and second-generation BTK inhibitors in the management of B-cell cancers, including CLL and MCL, among others, Develop appropriate single-agent, sequential, or combination strategies using BTK inhibitors in the management of patients with B-cell malignancies, Manage the unique spectrum of adverse events associated with the use of BTK inhibitors in patients with B-cell cancer.

Go online to PeerView.com/UVJ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In PeerView's latest “How I Think, How I Treat” webcast, leading experts, John C. Byrd, MD, Alexey V. Danilov, MD, PhD, and Nicole Lamanna, MD, explore the current evidence that underlies the use of first- and second-generation BTK inhibitors in diseases such as CLL, MCL, and others. They also share their personal insights and intra-institutional experiences in order to illustrate what the availability of BTK inhibitor therapy has meant for their practices. Learn how the experts have adapted to the BTK era! Upon completion of this activity, participants should be better able to: Describe the anticancer mechanisms of first- and second-generation BTK inhibitors, Cite updated guidelines and evidence surrounding the efficacy and safety of first- and second-generation BTK inhibitors in the management of B-cell cancers, including CLL and MCL, among others, Develop appropriate single-agent, sequential, or combination strategies using BTK inhibitors in the management of patients with B-cell malignancies, Manage the unique spectrum of adverse events associated with the use of BTK inhibitors in patients with B-cell cancer.

Go online to PeerView.com/UVJ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In PeerView's latest “How I Think, How I Treat” webcast, leading experts, John C. Byrd, MD, Alexey V. Danilov, MD, PhD, and Nicole Lamanna, MD, explore the current evidence that underlies the use of first- and second-generation BTK inhibitors in diseases such as CLL, MCL, and others. They also share their personal insights and intra-institutional experiences in order to illustrate what the availability of BTK inhibitor therapy has meant for their practices. Learn how the experts have adapted to the BTK era! Upon completion of this activity, participants should be better able to: Describe the anticancer mechanisms of first- and second-generation BTK inhibitors, Cite updated guidelines and evidence surrounding the efficacy and safety of first- and second-generation BTK inhibitors in the management of B-cell cancers, including CLL and MCL, among others, Develop appropriate single-agent, sequential, or combination strategies using BTK inhibitors in the management of patients with B-cell malignancies, Manage the unique spectrum of adverse events associated with the use of BTK inhibitors in patients with B-cell cancer.

Go online to PeerView.com/UVJ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In PeerView's latest “How I Think, How I Treat” webcast, leading experts, John C. Byrd, MD, Alexey V. Danilov, MD, PhD, and Nicole Lamanna, MD, explore the current evidence that underlies the use of first- and second-generation BTK inhibitors in diseases such as CLL, MCL, and others. They also share their personal insights and intra-institutional experiences in order to illustrate what the availability of BTK inhibitor therapy has meant for their practices. Learn how the experts have adapted to the BTK era! Upon completion of this activity, participants should be better able to: Describe the anticancer mechanisms of first- and second-generation BTK inhibitors, Cite updated guidelines and evidence surrounding the efficacy and safety of first- and second-generation BTK inhibitors in the management of B-cell cancers, including CLL and MCL, among others, Develop appropriate single-agent, sequential, or combination strategies using BTK inhibitors in the management of patients with B-cell malignancies, Manage the unique spectrum of adverse events associated with the use of BTK inhibitors in patients with B-cell cancer.

Go online to PeerView.com/UVJ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In PeerView's latest “How I Think, How I Treat” webcast, leading experts, John C. Byrd, MD, Alexey V. Danilov, MD, PhD, and Nicole Lamanna, MD, explore the current evidence that underlies the use of first- and second-generation BTK inhibitors in diseases such as CLL, MCL, and others. They also share their personal insights and intra-institutional experiences in order to illustrate what the availability of BTK inhibitor therapy has meant for their practices. Learn how the experts have adapted to the BTK era! Upon completion of this activity, participants should be better able to: Describe the anticancer mechanisms of first- and second-generation BTK inhibitors, Cite updated guidelines and evidence surrounding the efficacy and safety of first- and second-generation BTK inhibitors in the management of B-cell cancers, including CLL and MCL, among others, Develop appropriate single-agent, sequential, or combination strategies using BTK inhibitors in the management of patients with B-cell malignancies, Manage the unique spectrum of adverse events associated with the use of BTK inhibitors in patients with B-cell cancer.

Go online to PeerView.com/UVJ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In PeerView's latest “How I Think, How I Treat” webcast, leading experts, John C. Byrd, MD, Alexey V. Danilov, MD, PhD, and Nicole Lamanna, MD, explore the current evidence that underlies the use of first- and second-generation BTK inhibitors in diseases such as CLL, MCL, and others. They also share their personal insights and intra-institutional experiences in order to illustrate what the availability of BTK inhibitor therapy has meant for their practices. Learn how the experts have adapted to the BTK era! Upon completion of this activity, participants should be better able to: Describe the anticancer mechanisms of first- and second-generation BTK inhibitors, Cite updated guidelines and evidence surrounding the efficacy and safety of first- and second-generation BTK inhibitors in the management of B-cell cancers, including CLL and MCL, among others, Develop appropriate single-agent, sequential, or combination strategies using BTK inhibitors in the management of patients with B-cell malignancies, Manage the unique spectrum of adverse events associated with the use of BTK inhibitors in patients with B-cell cancer.

Go online to PeerView.com/UVJ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In PeerView's latest “How I Think, How I Treat” webcast, leading experts, John C. Byrd, MD, Alexey V. Danilov, MD, PhD, and Nicole Lamanna, MD, explore the current evidence that underlies the use of first- and second-generation BTK inhibitors in diseases such as CLL, MCL, and others. They also share their personal insights and intra-institutional experiences in order to illustrate what the availability of BTK inhibitor therapy has meant for their practices. Learn how the experts have adapted to the BTK era! Upon completion of this activity, participants should be better able to: Describe the anticancer mechanisms of first- and second-generation BTK inhibitors, Cite updated guidelines and evidence surrounding the efficacy and safety of first- and second-generation BTK inhibitors in the management of B-cell cancers, including CLL and MCL, among others, Develop appropriate single-agent, sequential, or combination strategies using BTK inhibitors in the management of patients with B-cell malignancies, Manage the unique spectrum of adverse events associated with the use of BTK inhibitors in patients with B-cell cancer.

Go online to PeerView.com/UVJ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In PeerView's latest “How I Think, How I Treat” webcast, leading experts, John C. Byrd, MD, Alexey V. Danilov, MD, PhD, and Nicole Lamanna, MD, explore the current evidence that underlies the use of first- and second-generation BTK inhibitors in diseases such as CLL, MCL, and others. They also share their personal insights and intra-institutional experiences in order to illustrate what the availability of BTK inhibitor therapy has meant for their practices. Learn how the experts have adapted to the BTK era! Upon completion of this activity, participants should be better able to: Describe the anticancer mechanisms of first- and second-generation BTK inhibitors, Cite updated guidelines and evidence surrounding the efficacy and safety of first- and second-generation BTK inhibitors in the management of B-cell cancers, including CLL and MCL, among others, Develop appropriate single-agent, sequential, or combination strategies using BTK inhibitors in the management of patients with B-cell malignancies, Manage the unique spectrum of adverse events associated with the use of BTK inhibitors in patients with B-cell cancer.